About the Cardiac Resynchronization Therapy Defibrillator (CRT-D) Market
Heart failure, a condition when the heart cannot pump enough blood to meet the body’s need, is one of the leading causes of death. Heart failure and stroke, if occurred together, can lead to major health problems or cause sudden death. Irregularity in ventricular rate can lead to reduction of diastolic dysfunction, a condition when there is abnormality in how the heart fills with blood causing pressure in the pulmonary vessel, leading to AF. Hence, patients with high risk of AF use CRT-D devices to minimize the risk associated with irregular heartbeat. The use of CRT-D devices enhances the functioning of the heart's electrical activity and improves heart rhythm. These devices are small in size and are placed below the collar bone.
Technavio’s analysts forecast the global cardiac resynchronization therapy defibrillator (CRT-D) market to grow at a CAGR of 8.36% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cardiac resynchronization therapy defibrillator (CRT-D) market for 2016-2020. To calculate the market size, we use revenue generated from the sales of various types of CRT-D devices.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cardiac Resynchronization Therapy Defibrillator (CRT-D) Market 2016-2020
Technavio recognizes the following companies as the key players in the global cardiac resynchronization therapy defibrillator (CRT-D) market: Boston Scientific, LivaNova, Medtronic, and St. Jude Medical.
Other Prominent Vendors in the market are: BIOTRONIK, Cook Medical, and Spectranetics.
Commenting on the report, an analyst from Technavio’s team said: “One trend that will boost the market is the growing popularity of robotic-assistance surgery. Robotic surgery is rapidly evolving and also successfully investigated for the implantation of CRT-D in patients. In few instances, the manual implantation of CRT-D may not be possible due to anatomic limitations. The introduction of robotic systems is one of the noteworthy advancements in minimally invasive cardiac surgeries. Robotic technology provides physicians with an excellent view of the operative field and the ability to manoeuvre instruments within close-fitting spaces with precision and control. Robotic surgical procedures help to reduce patients' hospital stays and facilitate better cost management.”
According to the report, a key growth driver is clinical considerations to make a switch to CRT-D technology. The switching from CRT-P to CRT-D, owing to clinical considerations, will propel the market growth. Clinical research studies show that CRT-D devices can reduce re-admissions to hospital for individuals with heart failure. In people with ischaemic cardiomyopathy or ischemic etiology, CRT-D implantation has showed better survival rate than CRT-P devices. There are incremental benefits in CRT-D devices compared to CRT-P devices, as it reduces the risk of sudden cardiac death (SCD) and improves the left ventricular function.
Further, the report states that one challenge that could restrict market growth is the high cost associated with open heart surgeries.
Boston Scientific, LivaNova, Medtronic, St. Jude Medical, BIOTRONIK, Cook Medical, Spectranetics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook